PMID- 1438990
OWN - NLM
STAT- MEDLINE
DCOM- 19921218
LR  - 20190827
IS  - 0167-0115 (Print)
IS  - 0167-0115 (Linking)
VI  - 41
IP  - 3
DP  - 1992 Oct 13
TI  - Desmethylimipramine pretreatment prevents 6-hydroxydopamine induced somatostatin 
      receptor reduction in the rat hippocampus.
PG  - 227-36
AB  - Several studies have shown anatomical and functional interconnections between 
      catecholaminergic and somatostatinergic systems. To assess whether somatostatin 
      (SS) may act presynaptically on catecholamine neurons, SS receptors were measured 
      using radioligand test-tube binding assays on synaptosomes from hippocampus and 
      frontoparietal cortex--areas that are innervated by catecholaminergic neurons 
      with different densities and that have a high number of SS receptors--from 
      control and 6-hydroxydopamine (6-OHDA)-treated rats. Intracerebroventricular 
      (i.c.v.) injection of the catecholamine neurotoxin 6-OHDA (0.78 mg free base/kg 
      of body weight in saline with 0.1% ascorbic acid) lowered hippocampal and 
      frontoparietal cortical noradrenaline (NA) and dopamine (DA) levels at 1 week 
      following the injection. Pretreatment of rats with desmethylimipramine (DMI) (40 
      mg/kg, intraperitoneal) prevented the drop in NA levels, but was not effective in 
      attenuating DA depletion in the two brain areas studied. Treatment with 6-OHDA 
      lowered the number of 125I-Tyr11-SS receptors in the hippocampus (130 +/- 19 vs. 
      266 +/- 16 fmol/mg protein, P < 0.001), whereas in the frontoparietal cortex a 
      non significant 20% reduction in receptor number was found. The dissociation 
      constants of 125I-Tyr11-SS binding to synaptosomes from frontoparietal cortex 
      (0.65 +/- 0.06 vs. 0.60 +/- 0.04, P not significant) and hippocampus (0.44 +/- 
      0.04 vs. 0.63 +/- 0.14, P not significant) were similar in control and treated 
      groups. Pretreatment with DMI reversed up to 80% of the effect of 6-OHDA on 
      hippocampus SS receptors. DMI alone had no observable effect on the number and 
      affinity of SS receptors. The 6-OHDA and the DMI treatment did not affect SLI 
      levels in the brain areas studied. These results suggest that a portion of the 
      hippocampal SS receptors may be localized presynaptically on the noradrenergic 
      and dopaminergic nerve terminals.
FAU - Lopez-Sanudo, S
AU  - Lopez-Sanudo S
AD  - Department of Biochemistry and Molecular Biology, Medical School, University of 
      Alcala, Alcala de Henares, Madrid, Spain.
FAU - Arilla, E
AU  - Arilla E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Regul Pept
JT  - Regulatory peptides
JID - 8100479
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, Somatostatin)
RN  - 8HW4YBZ748 (Oxidopamine)
RN  - TG537D343B (Desipramine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - Binding Sites
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Desipramine/administration & dosage/*pharmacology
MH  - Dopamine/metabolism
MH  - Hippocampus/*drug effects/metabolism
MH  - Injections, Intraperitoneal
MH  - Norepinephrine/metabolism
MH  - Oxidopamine/*pharmacology
MH  - Radioimmunoassay
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Somatostatin/*drug effects/metabolism
MH  - Synaptosomes/metabolism
EDAT- 1992/10/13 00:00
MHDA- 1992/10/13 00:01
CRDT- 1992/10/13 00:00
PHST- 1992/10/13 00:00 [pubmed]
PHST- 1992/10/13 00:01 [medline]
PHST- 1992/10/13 00:00 [entrez]
AID - 0167-0115(92)90116-C [pii]
AID - 10.1016/0167-0115(92)90116-c [doi]
PST - ppublish
SO  - Regul Pept. 1992 Oct 13;41(3):227-36. doi: 10.1016/0167-0115(92)90116-c.